Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA2118 in Osteoporosis
NCT05225857Phase 1Completed
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis comparing AGA2118 (MAD) with Placebo (MAD) (2 arms). Primary endpoints: Number of participants with treatment-emergent adverse events (TEAE), Number of participants with clinically significant changes in total calcium (albumin-adjusted) and 3 more. Started Jun 2022; status: completed.
02
Drugs
AGA2118
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05225857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225857.